Revelation Biosciences announced the exercise of outstanding warrants for $9.6 million in gross proceeds.
The warrants were issued by the Company on May 29, 2025, and represent 4,355,000 shares of common stock.
The offering is expected to close on September 11, 2025.
Gross Proceeds
$9.6 million in gross proceeds generated through the exercise of warrants.
Number of Shares
4,355,000 shares of common stock represented by the exercised warrants.
Offering Closing
The offering is expected to close on September 11, 2025.
Financial Advisor
Roth Capital Partners is acting as the Company's financial advisor for this transaction.
- Revelation Biosciences is focused on rebalancing inflammation using its proprietary formulation Gemini.
- The exercise of warrants is part of a financial transaction to strengthen the Company's position and fund its ongoing programs.
- The new Class I warrants will offer exercising holders the opportunity to purchase shares of common stock in a private placement.
The exercise of warrants represents a strategic move by Revelation Biosciences to raise funds and expand its programs. With the offering expected to close soon, the Company is poised for growth and continued innovation in the life sciences sector.